Supplementary Material

Project ECHO: telementoring to educate and support prescribing of HIV pre-exposure prophylaxis by community medical providers

Brian R. Wood^{A,B,D}, Maren S. Mann^C, Natalia Martinez-Paz^B, Kenton T. Unruh^B, Mary Annese^B, David H. Spach^{A,B}, John D. Scott^A and Joanne D. Stekler^{A,B}

^AUniversity of Washington Division of Allergy and Infectious Diseases, 1959 NE Pacific Street, Seattle, WA 98195, UA.

^BMountain West AIDS Education and Training Center (MW AETC), 325 9th Avenue, Seattle, WA 98104, USA.

^CUniversity of Washington School of Nursing, 1959 NE Pacific Street, Seattle, WA 98195, USA.

^DCorresponding author. Email: bwood2@uw.edu

Baseline Survey.

Follow-up Survey.

Baseline Survey

Pre-exposure prophylaxis (PrEP) is a strategy in which an HIV-uninfected person takes a medication daily to reduce the risk of HIV infection. The purpose of this survey is to learn about ECHO providers' current familiarity with, and use of, PrEP as well as potential interest in education and support for prescribing PrEP.

1.	Do you see the following categories of patients? (Check all that apply) ☐ Men who have sex with men ☐ Transgender women (male-to-female) and men (female-to-male) ☐ Intravenous drug users ☐ HIV-uninfected men or women whose partner is HIV-infected							
2.	What are your concerns about the use of PrEP as part of HIV prevention approaches (Check all that apply):							
	Effectiveness of PrEP Not certain who PrEP is right for							
	Staff time involved							
	Cost to patients							
	Unreimbursed costs to our clinic Adherence challenges							
	Drug resistance							
	Risk compensation (ie. decreased condom use)							
	Toxicity							
	Medication diversion (selling/sharing meds) Other (please explain below):							
3.	Have you discussed PrEP with any of your patients? (prescribing it) ☐ Yes	whether or not you ended up						
	If yes, with approximately how many patients?							
	□ No							
4.	Have you prescribed PrEP for any of your patients? ☐ Yes							
	If yes, for approximately how many patients?							
	If yes, in approximately what proportion did you r	` <u>*</u>						
spe	ecifically asking for PrEP)							
	□ No							
	□ n/a							

5. Which specific patient charapply)?	aracteristics wo	ould promp	t you to re	commend PrEP (check all that			
□ MSM with history of condomless sex □ Man or woman with HIV-seropositive partner on ARV therapy □ Man or woman with HIV-seropositive partner not on ARV therapy □ Man or woman with recent STI □ Commercial sex worker □ Serodiscordant couple interested in conception □ Active injection drug user □ Other (please explain):							
6. If one of your patients we comfortable would you be in		_		HIV prevention approach, how			
Very uncomfortable							
Somewhat uncomfortabl	e						
Neither comfortable nor	uncomfortable						
Somewhat comfortable							
Very comfortable							
7. How comfortable do you that apply):	feel talking wit	h your pat	ients about	the following topics? (Check all			
Very	Some	what	Somewh	at Very			
•			fortable	3			
PrEP candidacy							
Efficacy of PrEP							
Costs/insurance							
Risks/side effects							
Adherence							
Drug resistance							
Condoms/safe sex				_			
HIV transmission risk		_					
Monitoring on PrEP							
8. What topics would you like to have discussed in the ECHO didactic sessions?							
Overview of PrEP effica	•						
_	Assessing candidates for PrEP and baseline eval						
	Review of guidelines for prescribing PrEP						
Insurance/financial resou							
Adherence monitoring an		r DrED not	ionte				
HIV testing and other lab		n rittr pai	ients				
PrEP safety and drug resistance □							

PEP to PrEP transition Other (please explain):		
· · · · · · · · · · · · · · · · · · ·		
9. If an online tool were av	ilable to review PrEP data and prescribing guidelines and provide	de
additional PrEP education a	nd resources, how likely would you be to use it?	
Very likely		
Somewhat likely		
Neutral		
Somewhat unlikely		
Very unlikely		

THANKS. FEEL FREE TO WRITE ANY OTHER COMMENTS IN THE MARGINS!

Follow-up Survey

Thank you so much for participating in our survey. This survey is intended to evaluate the effectiveness of the ECHO sessions to provide education and support to you regarding HIV pre-exposure prophylaxis (PrEP). If you have any questions about this survey, please feel free to direct them towards Dr. Brian Wood (bwood2@uw.edu). Your answers to the following questions are **confidential** and will only be used within a larger data set as **anonymous** values. There are three parts to this survey, and **should take less than 15 minutes** of your time.

Name:						
Unique AETC ID:						
(HRSA requires a Unique ID [UID] for all trainees. If you do not have a UID already, you can create one by using the first 2 letters of your first and first 2 letters of your last name, followed by the 2-digit month and date of your birth. E.g.: Jane Smith, born 1/15 would be <i>jasm0115</i>)						
Age: □ <30 □ 30-39 □ 40-49 □ 50-59 □ ≥60						
Clinic location: Urban Suburban Rural						
Clinic setting: Academic health center Hospital-based clinic Federally Qualified Health Center Rural Health Center Private Practice Other, please specify:						
What is your professional discipline? ☐ MD ☐ APRN ☐ PA ☐ PharmD	 □ Social Work □ Case Manager □ Registered Nurse □ Other, please specify: 					

Please specify the # of years you have been in practice:

•	Currently in training							
	0-5							
	6-10							
	11-20							
□ >20								
Please specify the # of years you have been providing HIV care: Currently in training 0-5 6-10 11-20 >20								
How long have you been participating in the UW/MWAETC HIV ECHO sessions? □ <1 year □ 1-2 years □ 3-4 years □ >4 years								
Have you participated in any ECHO session that included HIV PrEP in the form of either a PrEP-related didactic talk or PrEP as part of a case discussion? ☐ Yes ☐ No								
If Yes, please continue. If No, please STOP.								
Part I: ECHO Sess	ions							
1. To what degree has HIV ECHO (didactics or case discussions) addressed your concerns about the following HIV PrEP topics?								
	Not at all	Slightly	Unsure	Moderately	Extremely			
Adherence								
challenges								
Cost to patients								
Who PrEP is								
intended for								
Risk of drug								

Resistance

Compensation (i.e. decreased condom use)

Risk

	<u>_</u> _			· · · · · · · · · · · · · · · · · · ·		
Toxicity/side effects						
2. To what degree h of PrEP as part of		•	vledge in each	of the following	specific areas	
	Not at all	Slightly	Unsure	Moderately	Extremely	
PrEP candidacy						
Baseline laboratory evaluation						
Insurance/Financial Resources						
Lab monitoring						
Supporting adherence						
If you presented an HIV PrEP case during an ECHO session: Please now consider one case you presented and answer the following questions, giving much detail as possible: a. What was your main HIV PrEP question? b. How much did presenting the case involving HIV PrEP influence your management that case? not at all slightly unsure moderately extremely						
c. Please describ	e how presenti	ng the case imp	pacted your ma	nagement of tha	t case:	
d. How did preso	enting the case	impact patient	outcomes?			
e. How would th	ne patient outco	me have been	different withou	ut ECHO?		
	another patient/client in your practice? ☐ not at all					

	unsure
	☐ moderately
	□ extremely
	If you observed an HIV PrEP case during an ECHO session (please complete even if
	you also presented a case):
	 a. How much did observing an HIV PrEP case presented during an ECHO session influence your management of patients/clients in your practice at risk for HIV acquisition? not at all slightly unsure moderately extremely
	Please give an example of a case in your practice that was influenced by knowledge gained from observing an HIV PrEP case or PrEP didactic during ECHO:
4.	To what degree do you feel that participation in HIV ECHO has helped you stay up-to-date on HIV PrEP guidelines? not at all slightly unsure moderately extremely
5.	To what degree do you feel that participation in ECHO has increased your likelihood to offer HIV PrEP? not at all slightly unsure moderately extremely Why or why not?
Pa	ort II: Community:
6.	Have you ever served as a resource to other providers in your area regarding HIV PrEP based on the knowledge you gained from ECHO participation? ☐ Yes ☐ No
7.	If you did not participate in ECHO, would you be referring your patients/clients at risk for HIV to another provider for HIV PrEP? ☐ Yes ☐ No

8.	 Prior to ECHO, who were you turning to for clinical advice regarding HIV PrEP? (select all that apply) 									
	☐ Another provider at my practice setting									
	☐ Another provider outside of my practice setting but not at the University of Washington									
		vider at the University of Washington								
	-	The University of Washington MEDCON consultation and referral service								
		·								
			iversity consultation and referral service							
	(PrEPline)		onal Clinician Consultation Center/Pre-Exposure Prophylaxis Service							
	□ None									
	☐ Other, plea	ase specify:								
Par	t III: ECHO	Participant and l	HIV PrEP							
9.	 Have you discussed HIV PrEP with any of your patients/clients? ☐ Yes ☐ No 									
	If yes, what per patients/clients	ercentage of those s)?	discussions were	initiated	by you (vs initi	iated by the				
	10. How comfortable do you feel discussing HIV PrEP with your patients/clients? very uncomfortable somewhat uncomfortable unsure somewhat comfortable very comfortable levery comfortable									
		1 77	G 1 4	TT	G 1.4	***				
		Very Uncomfortable	Somewhat Uncomfortable	Unsure	Somewhat Comfortable	Very Comfortable				
Pr	EP candidacy									
Ef	Efficacy of DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD									
	osts/Insurance									
co	coverage									
Ri	Risks/Side									
Ef	Effects									
A	dherence									
Dı	rug									
	Resistance									
Co	ondoms/Safe									
Se	×									

HIV										
transmission										
risk										
Laboratory										
monitoring on										
PrEP										
12. Can/do you prescribe HIV PrEP? ☐ Yes ☐ No										
13. If you are a pro ☐ Yes ☐ No	escriber, have you	ever prescribed	HIV PrEI	of for any of you	ır patients/clients?					
If yes, for appr	roximately how m	nany patients/clier	nts?							
14. What concerns have prevented you from prescribing HIV PrEP? (select all that apply) Concern about adherence Concern about future resistance Cost/payer issues Concern about side effects Insufficient real-world evidence for HIV PrEP efficacy Other reasons, please specify:										
15. What topics w HIV PrEP?	ould you like to h	ave discussed in	future EC	HO didactic se	ssions regarding					
16. Would it be okay if we contact you either by email or phone in the future for a short conversation to gather more detail regarding your responses?☐ Yes☐ No										
Thank you for your participation!										
Sincerely,										
The ECHO Team										